펜 니들 시장 보고서 : 유형, 바늘 길이, 치료법, 구입 형태, 최종 사용자 및 지역별(2026-2034년)

The global pen needles market size reached USD 4.7 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 13.1 Billion by 2034, exhibiting a growth rate (CAGR) of 11.67% during 2026-2034. The market is driven by the rising prevalence of diabetes and chronic diseases, expanding geriatric population, increasing investment in the healthcare sector, rapid technological advancements, growing self-administration of insulin, and the imposition of favorable reimbursement policies.

PEN NEEDLES MARKET ANALYSIS:

• Major Market Drivers: The increasing prevalence of diabetes and other chronic illnesses that require regular insulin injections has been leading to a higher demand for pen needles. Furthermore, technological advancements in design, such as ultra-fine and shorter needles, in combination with favorable reimbursement policies and government efforts, are contributing to the market growth.
• Key Market Trends: The burgeoning popularity of insulin self-administration, coupled with ongoing product advances such as ergonomic designs and safety features, is attracting new customers and positively improving the dynamics of the market. Furthermore, the introduction of e-commerce platforms and online sales channels that make pen needles more accessible is fueling the expansion of this market.
• Geographical Trends: Europe is currently dominating the market, due to increased diabetes prevalence, advanced healthcare infrastructure, and robust reimbursement systems. Other regions are also experiencing growth as a result of heightened product awareness, upgraded healthcare facilities, and the rising disposable incomes.
• Competitive Landscape: Some of the major market players in the pen needles industry include A. Menarini Diagnostics srl, Advancare Pharma, Arkray Inc., B. Braun Melsungen AG, Becton Dickinson and Company, Hindustan Syringes & Medical Devices Ltd., HTL Strefa SA, Novo Nordisk A/S, Owen Mumford Ltd., Simple Diagnostics, Trividia Health Inc. (Sinocare), Ultimed Inc., among many others.
• Challenges and Opportunities: The high cost of improved pen needles, along with limited reimbursement in some jurisdictions, poses an obstacle to market expansion. However, growing knowledge and education about diabetes management have created opportunities to boost the market in emerging countries.

PEN NEEDLES MARKET TRENDS:

Increasing Prevalence of Diabetes and Other Chronic Diseases

The rising prevalence of diabetes and other chronic diseases across the globe is a major factor driving the pen needles market growth. According to the International Diabetes Federation's (IDF) Diabetes Atlas, 10.5% of the adult population aged 20 to 79 had diabetes in 2021, with over half unaware of the diagnosis. By 2045, this forecast predicts that one in every eight adults, or nearly 783 million, will have diabetes, which is an approximately 46% rise. In line with this, diabetes management necessitates frequent monitoring and insulin administration, which is accomplished with insulin pens equipped with pen needles. Pen needles are an indispensable tool for diabetes patients who require frequent insulin injections due to their ease and user-friendliness.

Expanding Geriatric Population

The pen needles market forecast highlights that the expanding geriatric population is a significant factor that is resulting in the growth of this market. Geriatric adults are more susceptible to chronic diseases, including diabetes, due to age-related physiological changes and a higher prevalence of comorbidities. According to the World Health Organization (WHO), the proportion of the world's population over 60 years is projected to nearly double from 12% in 2015 to 22% by 2050. This demographic shift has profound implications for healthcare systems and the demand for medical devices. Additionally, pen needles that are designed with features like easy handling, minimal pain, and safety mechanisms are beneficial for this age group. As the geriatric population continues to grow, the demand for products that are tailored to their specific needs is expected to increase, driving the expansion of the market.

Growing Investment in the Healthcare Sector

The increasing funding in the healthcare industry by several countries is strengthening the pen needle market share. For example, in 2022, Europe's overall government spending on health totaled €1221 Billion, or 7.7% of GDP. Similarly, India's public healthcare spending accounted for 2.1% of GDP in FY23 and 2.2% in FY22. This expansion has been allowing for improved diagnosis, monitoring, and management of illnesses such as diabetes, which drives up the demand for pen needles. Furthermore, the availability of cost-effective insurance coverage and reimbursement schemes have been encouraging patients to explore the use of insulin pens and pen needles as a treatment option. For instance, 92.1 percent of people, or 304.0 million in the U.S., had health insurance at some point during 2022, which also increased the pen needles demand.

PEN NEEDLES MARKET SEGMENTATION:

Breakup by Type:

• Standard Pen Needles
• Safety Pen Needles

Standard pen needles accounts for the majority of the market share

As per the pen needles market outlook and analysis, the standard pen needles segment represented the largest share, driven by their widespread usage and acceptance among patients and healthcare providers. These needles are designed to fit most insulin pens and are known for their versatility, ease of use, and availability in various lengths and gauges. Moreover, standard pen needles are preferred due to their cost-effectiveness and the broad range of options that ensure compatibility with various insulin delivery systems. Besides this, the continuous improvements in design and technology, which enhance comfort and reduce pain during injections, are positively impacting the pen needle market value.

Breakup by Needle Length:

• 4mm
• 5mm
• 6mm
• 8mm
• 10mm
• 12mm

8mm holds the largest share of the industry

Based on the pen needles market report and trends, the 8mm needle length segment holds the largest share in the market, attributed to its balanced efficacy and comfort for a wide range of patients. This length is considered optimal for subcutaneous insulin delivery, ensuring adequate penetration to the subcutaneous tissue while minimizing the risk of intramuscular injection. Moreover, the 8mm needles are widely recommended by healthcare providers due to their versatility, making them suitable for adults and children. Along with this, the extensive use of 8mm needles in clinical practice, coupled with patient familiarity and acceptance, is enhancing the pen needles market size.

Breakup by Therapy:

• Insulin
• GLP-1
• Growth Hormones

Insulin represents the leading market segment

According to the pen needles market overview and segmentation, insulin therapy constituted the largest share, driven by the growing prevalence of diabetes and the necessity of insulin administration for effective disease management. In line with this, insulin therapy requires frequent and precise injections, making pen needles an essential tool for diabetic patients. Moreover, the rising convenience, accuracy, and reduced pain associated with pen needles that enhance patient compliance and quality of life are contributing to the market growth. Additionally, the development of advanced insulin pens and continuous innovations in product technology are supporting the pen needle market price trends.

Breakup by Mode of Purchase:

• Retail
• Non-Retail

Retail exhibits a clear dominance in the market

As per the pen needles market research report, the retail segment represented the largest share, driven by the convenience and accessibility it offers to consumers. Retail pharmacies and online stores provide an easy and immediate access point for patients as they offer quick supplies without the need for a medical facility visit. Besides this, the broad distribution networks of retail channels ensure widespread availability, catering to urban and rural populations. Additionally, retail outlets offer a variety of brands and products, allowing patients to choose pen needles that best meet their needs and preferences.

Breakup by End User:

• Hospitals and Clinics
• Home Healthcare
• Others

Hospitals and clinics dominate the market

Hospitals and clinics constituted the largest segment, driven by the high volume of medical procedures and chronic disease management performed in these settings. They are primary healthcare providers where a significant number of diabetes patients receive their diagnosis, treatment plans, and ongoing management, necessitating a steady supply of pen needles for insulin administration and other injectable therapies. Moreover, these healthcare facilities prioritize patient safety and efficacy, opting for high-quality needles to ensure precise and comfortable medication delivery. Additionally, hospitals and clinics serve as the first point of education for patients on the correct use of these needles, boosting the market growth.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Europe leads the market, accounting for the largest pen needles market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe represents the largest regional market for pen needles.

Europe holds the largest segment in the pen needles industry, driven by a combination of high diabetes prevalence, advanced healthcare infrastructure, and supportive government policies. In line with this, the robust healthcare systems that provide extensive access to diabetes management tools, coupled with increased support from strong reimbursement frameworks that reduce the financial burden on patients, are boosting the market growth. Along with this, the high awareness of diabetes care, with proactive public health campaigns and educational programs that promote the use of these pens, is favoring the market growth. Additionally, the presence of several leading medical device manufacturers that foster innovation and boost the availability of advanced needle technologies is stimulating the pen needle market revenue.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the pen needles industry include:

• A. Menarini Diagnostics srl
• Advancare Pharma
• Arkray Inc.
• B. Braun Melsungen AG
• Becton Dickinson and Company
• Hindustan Syringes & Medical Devices Ltd.
• HTL Strefa SA
• Novo Nordisk A/S
• Owen Mumford Ltd.
• Simple Diagnostics
• Trividia Health Inc. (Sinocare)
• Ultimed Inc.

The major pen needle companies are focusing on innovation, strategic partnerships, and expanding their global footprint to maintain and enhance their market positions. They are focusing on innovating with ultra-fine and shorter needles to improve patient comfort and compliance. Moreover, some players are leveraging their strong presence in the insulin delivery market to integrate advanced pen needles with their insulin pens to ensure seamless and effective diabetes management. Besides this, they are working on expanding their product portfolio with technologically advanced solutions and enhancing distribution networks to reach a broader audience. Moreover, these companies are actively involved in strategic collaborations and acquisitions to strengthen their market presence and capabilities.

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Pen Needles Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Standard Pen Needles
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Safety Pen Needles
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast

7 Market Breakup by Needle Length

• 7.1 4mm
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 5mm
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 6mm
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 8mm
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 10mm
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast
• 7.6 12mm
  • 7.6.1 Market Trends
  • 7.6.2 Market Forecast

8 Market Breakup by Therapy

• 8.1 Insulin
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 GLP-1
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Growth Hormones
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Mode of Purchase

• 9.1 Retail
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Non-Retail
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast

10 Market Breakup by End User

• 10.1 Hospitals and Clinics
  • 10.1.1 Market Trends
  • 10.1.2 Market Forecast
• 10.2 Home Healthcare
  • 10.2.1 Market Trends
  • 10.2.2 Market Forecast
• 10.3 Others
  • 10.3.1 Market Trends
  • 10.3.2 Market Forecast

11 Market Breakup by Region

• 11.1 North America
  • 11.1.1 United States
    • 11.1.1.1 Market Trends
    • 11.1.1.2 Market Forecast
  • 11.1.2 Canada
    • 11.1.2.1 Market Trends
    • 11.1.2.2 Market Forecast
• 11.2 Asia-Pacific
  • 11.2.1 China
    • 11.2.1.1 Market Trends
    • 11.2.1.2 Market Forecast
  • 11.2.2 Japan
    • 11.2.2.1 Market Trends
    • 11.2.2.2 Market Forecast
  • 11.2.3 India
    • 11.2.3.1 Market Trends
    • 11.2.3.2 Market Forecast
  • 11.2.4 South Korea
    • 11.2.4.1 Market Trends
    • 11.2.4.2 Market Forecast
  • 11.2.5 Australia
    • 11.2.5.1 Market Trends
    • 11.2.5.2 Market Forecast
  • 11.2.6 Indonesia
    • 11.2.6.1 Market Trends
    • 11.2.6.2 Market Forecast
  • 11.2.7 Others
    • 11.2.7.1 Market Trends
    • 11.2.7.2 Market Forecast
• 11.3 Europe
  • 11.3.1 Germany
    • 11.3.1.1 Market Trends
    • 11.3.1.2 Market Forecast
  • 11.3.2 France
    • 11.3.2.1 Market Trends
    • 11.3.2.2 Market Forecast
  • 11.3.3 United Kingdom
    • 11.3.3.1 Market Trends
    • 11.3.3.2 Market Forecast
  • 11.3.4 Italy
    • 11.3.4.1 Market Trends
    • 11.3.4.2 Market Forecast
  • 11.3.5 Spain
    • 11.3.5.1 Market Trends
    • 11.3.5.2 Market Forecast
  • 11.3.6 Russia
    • 11.3.6.1 Market Trends
    • 11.3.6.2 Market Forecast
  • 11.3.7 Others
    • 11.3.7.1 Market Trends
    • 11.3.7.2 Market Forecast
• 11.4 Latin America
  • 11.4.1 Brazil
    • 11.4.1.1 Market Trends
    • 11.4.1.2 Market Forecast
  • 11.4.2 Mexico
    • 11.4.2.1 Market Trends
    • 11.4.2.2 Market Forecast
  • 11.4.3 Others
    • 11.4.3.1 Market Trends
    • 11.4.3.2 Market Forecast
• 11.5 Middle East and Africa
  • 11.5.1 Market Trends
  • 11.5.2 Market Breakup by Country
  • 11.5.3 Market Forecast

12 SWOT Analysis

• 12.1 Overview
• 12.2 Strengths
• 12.3 Weaknesses
• 12.4 Opportunities
• 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

• 14.1 Overview
• 14.2 Bargaining Power of Buyers
• 14.3 Bargaining Power of Suppliers
• 14.4 Degree of Competition
• 14.5 Threat of New Entrants
• 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

• 16.1 Market Structure
• 16.2 Key Players
• 16.3 Profiles of Key Players
  • 16.3.1 A. Menarini Diagnostics srl
    • 16.3.1.1 Company Overview
    • 16.3.1.2 Product Portfolio
  • 16.3.2 Advancare Pharma
    • 16.3.2.1 Company Overview
    • 16.3.2.2 Product Portfolio
  • 16.3.3 Arkray Inc.
    • 16.3.3.1 Company Overview
    • 16.3.3.2 Product Portfolio
  • 16.3.4 B. Braun Melsungen AG
    • 16.3.4.1 Company Overview
    • 16.3.4.2 Product Portfolio
    • 16.3.4.3 SWOT Analysis
  • 16.3.5 Becton Dickinson and Company
    • 16.3.5.1 Company Overview
    • 16.3.5.2 Product Portfolio
    • 16.3.5.3 Financials
    • 16.3.5.4 SWOT Analysis
  • 16.3.6 Hindustan Syringes & Medical Devices Ltd.
    • 16.3.6.1 Company Overview
    • 16.3.6.2 Product Portfolio
  • 16.3.7 HTL Strefa S A
    • 16.3.7.1 Company Overview
    • 16.3.7.2 Product Portfolio
  • 16.3.8 Novo Nordisk A/S
    • 16.3.8.1 Company Overview
    • 16.3.8.2 Product Portfolio
    • 16.3.8.3 Financials
    • 16.3.8.4 SWOT Analysis
  • 16.3.9 Owen Mumford Ltd.
    • 16.3.9.1 Company Overview
    • 16.3.9.2 Product Portfolio
    • 16.3.9.3 SWOT Analysis
  • 16.3.10 Simple Diagnostics
    • 16.3.10.1 Company Overview
    • 16.3.10.2 Product Portfolio
  • 16.3.11 Trividia Health Inc. (Sinocare)
    • 16.3.11.1 Company Overview
    • 16.3.11.2 Product Portfolio
  • 16.3.12 Ultimed Inc.
    • 16.3.12.1 Company Overview
    • 16.3.12.2 Product Portfolio